Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Outset Medical (OM) over the last 7 years, with Q4 2025 value amounting to -$120000.0.

  • Outset Medical's Change in Accured Expenses fell 11035.38% to -$120000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.1 million, marking a year-over-year decrease of 1776.32%. This contributed to the annual value of -$6.1 million for FY2025, which is 1776.32% down from last year.
  • Outset Medical's Change in Accured Expenses amounted to -$120000.0 in Q4 2025, which was down 11035.38% from $1.1 million recorded in Q3 2025.
  • In the past 5 years, Outset Medical's Change in Accured Expenses ranged from a high of $5.0 million in Q3 2021 and a low of -$11.5 million during Q1 2022
  • For the 5-year period, Outset Medical's Change in Accured Expenses averaged around -$460000.0, with its median value being $1.1 million (2024).
  • Within the past 5 years, the most significant YoY rise in Outset Medical's Change in Accured Expenses was 200400.0% (2024), while the steepest drop was 19260.36% (2024).
  • Quarter analysis of 5 years shows Outset Medical's Change in Accured Expenses stood at $4.6 million in 2021, then plummeted by 51.23% to $2.2 million in 2022, then plummeted by 33.82% to $1.5 million in 2023, then decreased by 22.06% to $1.2 million in 2024, then crashed by 110.35% to -$120000.0 in 2025.
  • Its last three reported values are -$120000.0 in Q4 2025, $1.1 million for Q3 2025, and $1.5 million during Q2 2025.